Prediabetes affects millions of individuals worldwide and represents an established harbinger of cardiovascular disease. While clinical guidelines emphasize restoring normal blood sugar levels, restoring normoglycaemia alone might not eliminate vascular danger. Recent evidence underscores the crucial role of cumulative metabolic stress, particularly captured through TyG-derived indices. These composite biomarkers combine fasting triglycerides and glucose with anthropometric measurements of adiposity. Evaluating these parameters reveals whether underlying insulin resistance continues to compromise vascular integrity. Consequently, clinicians must look beyond standard glycemic thresholds to understand how metabolic memory and central obesity modulate long-term cardiovascular outcomes in this vulnerable population.

Understanding Glycaemic Transitions and TyG-Derived Indices

Patients with prediabetes frequently transition between different glycaemic states over time. Some individuals progress rapidly toward overt type 2 diabetes, whereas others successfully revert to normoglycaemia through lifestyle alterations or pharmacotherapy. However, clinicians often assume that returning to normoglycaemia completely resets cardiovascular disease risk. To evaluate this assumption, researchers investigated the China Health and Retirement Longitudinal Study cohort. They tracked 1,468 adults with prediabetes to explore how dynamic glycaemic transitions and insulin resistance patterns interact.

The investigators specifically analyzed cumulative TyG-derived indices to capture comprehensive metabolic dysfunction. These markers included the standard triglyceride-glucose metric along with combined adiposity parameters:

• TyG-ABSI (A Body Shape Index)
• TyG-BRI (Body Roundness Index)
• TyG-CVAI (Chinese Visceral Adiposity Index)
• TyG-WWI (Weight-Adjusted Waist Index)

These metrics integrate glucolipotoxicity and visceral fat distribution across multiple examination waves. Therefore, they offer a dynamic portrait of continuous cardiometabolic stress. Unlike single fasting plasma glucose tests, cumulative indices reflect prolonged physiological strain on endothelial cells. By tracking these trajectory markers over several years, physicians can distinguish between superficial glycaemic recovery and true metabolic restoration. This distinction proves essential for accurate long-term cardiovascular prognosis.

Key Study Findings on Reversion and Cardiovascular Risk

Over a median follow-up of 5.0 years, the longitudinal study documented 294 incident cardiovascular disease events. When researchers compared participants based solely on glycaemic trajectory, progression to diabetes predictably increased cardiovascular risk by 53 percent compared with persistent prediabetes. In contrast, simple reversion to normoglycaemia failed to show a statistically significant protective advantage against cardiovascular events. This striking observation highlights a critical limitation in relying exclusively on blood glucose normalization as a surrogate endpoint for vascular health.

Furthermore, joint exposure analyses revealed profound risk stratification governed by underlying insulin resistance and adiposity. Participants who achieved normoglycaemia while maintaining low cumulative TyG-derived indices demonstrated no elevated risk of cardiovascular events. Conversely, individuals who reverted to normoglycaemia but maintained high cumulative indices experienced substantially higher cardiovascular hazard ratios, ranging from 1.55 to 2.05.

Among the subset of patients who normalized their blood glucose, those with elevated cumulative indices faced an adjusted cardiovascular risk between 1.89-fold and 2.52-fold higher. Consequently, the study confirms that residual insulin resistance and visceral adiposity negate the expected cardiovascular benefits of glucose normalization. These findings emphasize that metabolic health involves much more than fasting blood sugar.

The Biological Burden of Persistent Insulin Resistance and Visceral Adiposity

The persistence of vascular risk despite normoglycaemia stems from deep pathophysiological mechanisms tied to visceral adiposity and insulin resistance. Visceral adipose tissue operates as an active endocrine organ that secretes pro-inflammatory cytokines, free fatty acids, and prothrombotic mediators. Even when pancreatic beta cells compensate sufficiently to normalize circulating glucose, chronic hyperinsulinemia and lipid spillover persist. Consequently, these circulating factors stimulate systemic endothelial dysfunction, promote vascular smooth muscle proliferation, and accelerate atherogenesis.

Moreover, hepatic lipid accumulation perpetuates the overproduction of atherogenic triglyceride-rich lipoproteins. This continuous lipid flux induces oxidative stress within the vascular endothelium and impairs nitric oxide bioavailability. In addition, previous dysglycaemia frequently induces lasting epigenetic modifications within vascular tissue, a phenomenon often described as metabolic memory. Because macroscopic vascular remodeling and chronic low-grade vascular inflammation continue unabated, microvascular and macrovascular beds remain vulnerable to thrombosis and ischaemia.

Therefore, lowering glucose levels without reducing central adiposity leaves the core vascular injury pathways fully operational. TyG-derived indices effectively capture this multifaceted metabolic dysfunction by synthesizing lipid overflow, insulin insensitivity, and anatomical fat accumulation into a reliable prognostic measurement.

Clinical Implications for Cardiometabolic Risk Stratification

These empirical findings carry immediate clinical implications for primary care physicians, endocrinologists, and cardiologists. First, practitioners must recognize that returning to a normal HbA1c or fasting glucose level does not guarantee cardiovascular safety. If a patient remains centrally obese or retains dyslipidemia, their vascular risk remains substantially elevated. Therefore, relying exclusively on standard glycaemic tests fosters a false sense of security among both clinicians and patients.

Second, integrating TyG-derived indices into routine practice offers an accessible, cost-effective risk stratification tool. Because these formulas utilize standard biochemical panels (fasting blood glucose and triglycerides) alongside basic anthropometric measures (waist circumference, height, and weight), clinics can calculate them without expensive specialized testing. For instance, computing the TyG-BRI or TyG-CVAI allows clinicians to identify high-risk individuals who require aggressive risk modification.

Furthermore, clinical protocols should incorporate cumulative metabolic assessments over time rather than single snapshot measurements. Tracking the trajectory of insulin resistance and adiposity helps clinicians determine whether therapeutic interventions are effectively modifying vascular risk. Consequently, comprehensive cardiometabolic risk assessments should supersede isolated glycaemic monitoring in routine chronic disease care.

Practical Strategies for Addressing Residual Risk Beyond Glycaemia

To mitigate residual cardiovascular danger in prediabetes, clinicians must implement multifaceted therapeutic strategies targeting the entire cardiometabolic axis. Lifestyle interventions should focus on achieving sustained visceral fat loss rather than mere caloric restriction. For example, structured aerobic exercise combined with progressive resistance training enhances peripheral insulin sensitivity, reduces hepatic steatosis, and diminishes visceral depots. Furthermore, nutritional counselling should emphasize Mediterranean or low-glycaemic-index dietary patterns rich in whole foods, unsaturated fats, and dietary fibre.

In addition to lifestyle modifications, physicians should optimize concomitant cardiovascular risk factors aggressively. This management includes maintaining strict blood pressure targets, optimizing lipid fractions with statins or lipid-lowering agents, and considering insulin-sensitizing pharmacotherapies where indicated. Emerging therapeutics such as glucagon-like peptide-1 (GLP-1) receptor agonists and dual GIP/GLP-1 receptor agonists provide robust visceral fat reduction alongside glycaemic normalization.

Moreover, regular follow-up should involve monitoring comprehensive lipid panels, waist-to-height ratios, and calculated TyG-based parameters. By treating the underlying insulin resistance and visceral adiposity directly, clinicians can translate normoglycaemic reversion into genuine, lasting cardiovascular protection.

Frequently Asked Questions

Why does cardiovascular risk remain elevated despite normoglycaemia reversion?

Reverting to normoglycaemia does not automatically resolve underlying metabolic disturbances. Persistent visceral adiposity and chronic insulin resistance continue to promote systemic low-grade inflammation, oxidative stress, and endothelial dysfunction. Furthermore, elevated triglyceride levels, atherogenic dyslipidemia, and metabolic memory maintain an adverse vascular environment. Consequently, patients who normalize glucose while retaining high insulin resistance remain highly vulnerable to incident myocardial infarction and stroke.

What makes TyG-derived indices superior to standard glucose metrics?

Standard glucose metrics only evaluate circulating glycaemia at a single timepoint, often missing deeper metabolic derangements. In contrast, TyG-derived indices integrate fasting blood glucose, circulating triglycerides, and precise anthropometric measurements of central adiposity. Therefore, these composite markers reflect the dual burden of glucolipotoxicity and visceral fat accumulation. This combined assessment provides a far more accurate appraisal of cumulative cardiovascular risk and long-term vascular pathology.

How should clinicians manage patients with high cumulative metabolic burden?

Clinicians should implement comprehensive management plans targeting both glycaemia and visceral adiposity. First, recommend structured exercise and heart-healthy dietary patterns to diminish central fat stores. Next, optimize blood pressure and lipid fractions with appropriate pharmacological agents. Additionally, clinicians should consider weight-loss or insulin-sensitizing therapeutics. Regularly monitoring TyG-derived indices ensures that treatment successfully alleviates residual vascular danger over time.

Disclaimer: This content is for informational and educational purposes only and is not intended as medical advice. It should not be used to diagnose or treat any medical condition. Always consult a qualified healthcare provider with any questions you may have regarding a medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Cai H et al. Insulin Resistance-Adiposity Burden and Incident Cardiovascular Disease Across Glycaemic Transitions in Prediabetes: Risk Stratification After Reversion to Normoglycaemia. Diabetes Obes Metab. 2026 Aug 25. doi: 10.1111/dom.71280. PMID: 42642351.
2. Vistisen D, Kivimäki M, Perreault L, et al. Reversion from prediabetes to normoglycaemia and risk of cardiovascular disease and mortality: the Whitehall II cohort study. Diabetologia. 2019;62(8):1385-1390.
3. Ding X, Wang X, Wu J, Zhang M, Cui M. Triglyceride-glucose index and the incidence of atherosclerotic cardiovascular disease: a meta-analysis of cohort studies. Cardiovasc Diabetol. 2021;20(1):76.